Oxcia’s CEO Ulrika Warpman Berglund created large interest with the poster presentation of the unique dual mechanism of action of OXC-101 and its potent and well tolerated anti-cancer effects at the 6th Annual DDR Inhibitors Summit in Boston. The conference… Continue reading Attended DDR Inhibitors Summit in Boston
News
World Cancer Day
Today, the 4th of February, is the World Cancer Day! The purpose of the World Cancer Day is to increase knowledge about the situation of cancer patients and their relatives. It is a global uniting initiative led by the Union for International Cancer… Continue reading World Cancer Day
New article enforces the cancer cell selective killing of OXC-101
New peer-reviewed article in Biomolecules, enforces the cancer cell selective killing of OXC-101. In a recently published article, Oxcia and its collaborators at Karolinska institute, shows that OXC-101 is extra efficacious in cancer cells overexpressing c-Myc (Hendriksson et al, Biomolecules… Continue reading New article enforces the cancer cell selective killing of OXC-101
Oxcia attends DDR Inhibitors Summit in Boston
Oxcia’s CEO Ulrika Warpman Berglund will attend the DDR Inhibitors Summit in Boston January 24-26th and present a poster describing the unique dual mechanism of action of OXC-101 and its potent and well tolerated anti-cancer effects. DDR is short for… Continue reading Oxcia attends DDR Inhibitors Summit in Boston
IPF awareness month
About 400,000 people in Europe live with Pulmonary Fibrosis and some 100,000 patients die each year from the disease. The most common type of PF is IPF (Idiopathic Pulmonary Fibrosis), accounting for 200,000 patients in Europe. EU-IPFF, the European Patient… Continue reading IPF awareness month
Oxcia welcomes Senior Scientist Sandra Ekstedt
Sandra Ekstedt has joined Oxcia as Senior Scientist, a very welcome reinforcement as Sandra has a strong background in inflammation, immunology and airway disease with a PhD and over 10 years of work in the field. Sandra will primarily work… Continue reading Oxcia welcomes Senior Scientist Sandra Ekstedt
LSX Nordic Congress
Oxcia is happy about all productive meetings and insightful discussions with pharma and investors at the LSX Nordic Congress. If you missed the congress and want to learn more about Oxcia and our exciting projects, please get in touch or… Continue reading LSX Nordic Congress
Translational Director strengthens Oxcia’s team
The 1st of September William Stafford, PhD joined Oxcia AB as Translational Director. William has a background in oncology and redox-biology from the Karolinska Institutet. He developed his PhD work toward commercialization through Karolinska Institutet Innovations AB, leading to an… Continue reading Translational Director strengthens Oxcia’s team
Oxcia is at the LSX Nordic congress 6-7th of September
Oxcia will be meeting potential partners and investors at the LSX Nordic Congress for Nordic Life Science next week. Please get in contact if you are there and want to meet.
Large interest in OXC-201 at the IPF Summit in Boston
There was a lot of interest in Oxcias poster describing OXC-201, the promising novel treatment strategy for Idiopathic pulmonary fibrosis (IPF), at the IPF summit in Boston 29th of August to 1st of September. A new treatment is desperately needed.… Continue reading Large interest in OXC-201 at the IPF Summit in Boston